Selection of lansoprazole from an FDA-approved drug library to inhibit the Alzheimer’s disease seed-dependent formation of tau aggregates

Selection of lansoprazole from an FDA-approved drug library to inhibit the Alzheimer’s disease seed-dependent formation of tau aggregates

The efficacy of current treatments is still insufficient for Alzheimer’s disease (AD), the most common cause of Dementia. Out of the two pathological hallmarks of AD amyloid-β plaques and neurofibrillary tangles, comprising of tau protein, tau pathology strongly correlates with the symptoms of AD. P...

Full description

Bibliographic Details
Main Authors: Ahmed Imtiaz, Shotaro Shimonaka, Mohammad Nasir Uddin, Montasir Elahi, Koichi Ishiguro, Masato Hasegawa, Nobutaka Hattori, Yumiko Motoi
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-03-01
Series:Frontiers in Aging Neuroscience
Subjects:
tau
aggregation
Alzheimer’s disease
filament
seed
drug reposition
Online Access:https://www.frontiersin.org/articles/10.3389/fnagi.2024.1368291/full

Internet

https://www.frontiersin.org/articles/10.3389/fnagi.2024.1368291/full

Similar Items